Results 181 to 190 of about 5,099,009 (221)
Some of the next articles are maybe not open access.
Ibrutinib for Mantle Cell Lymphoma
Future Oncology, 2016Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile in relapsed/refractory MCL.
David L, Tucker, Simon A, Rule
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2020
Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity.
Preetesh, Jain, Michael, Wang
openaire +2 more sources
Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity.
Preetesh, Jain, Michael, Wang
openaire +2 more sources
Lenalidomide for mantle cell lymphoma
Expert Review of Hematology, 2015Mantle cell lymphoma accounts for 6% of all non-Hodgkin lymphomas. It is a biologically and clinically heterogeneous disease and treatment may be difficult, since most patients present at an older age, being unable to undergo intensive chemotherapy. Lenalidomide is an approved medication for relapsed mantle cell lymphoma in patients who received at ...
Alan P, Skarbnik, Andre H, Goy
openaire +2 more sources
Mantle cell lymphoma diagnosis
Annales de biologie clinique, 2013Recent classifications of non-Hodgkin's lymphomas based on combination of morphologic, immunophenotypic, and cytogenetic criteria have individualized mantle cell lymphoma (MCL). This clinico-biological entity which accounts for 3 to 10% of all non-Hodgkin's lymphomas, now appears to be a biological and therapeutic model for the understanding and ...
Mohammed, Choukri +7 more
openaire +2 more sources
MicroRNAs in mantle cell lymphoma
Leukemia & Lymphoma, 2013Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin lymphoma. New treatment modalities, including intensive induction regimens with immunochemotherapy and autologous stem cell transplant, have improved survival. However, many patients still relapse, and there is a need for novel therapeutic strategies.
Husby, Simon +2 more
openaire +3 more sources
Leukemia & Lymphoma, 2013
Over the past decade, it has become increasingly clear that mantle cell lymphoma (MCL) is a more heterogeneous disease than originally recognized. Several groups have reported on a subgroup of patients with a less aggressive course than expected resulting in the term "indolent MCL".
Eric D, Hsi, Peter, Martin
openaire +2 more sources
Over the past decade, it has become increasingly clear that mantle cell lymphoma (MCL) is a more heterogeneous disease than originally recognized. Several groups have reported on a subgroup of patients with a less aggressive course than expected resulting in the term "indolent MCL".
Eric D, Hsi, Peter, Martin
openaire +2 more sources
Mantle Cell Lymphoma: An Update
Leukemia & Lymphoma, 1992Mantle cell lymphoma is a distinctive pathologic entity that incorporates the previous histopathologic categories of centrocytic lymphoma and lymphocytic lymphoma of intermediate differentiation. These lymphomas are characterized by common histologic and immunologic characteristics that suggest derivation from the follicular mantle zone.
M, Raffeld +3 more
openaire +2 more sources
The Epigenetics of Mantle Cell Lymphoma
Current Treatment Options in Oncology, 2007There is no consensus treatment for newly diagnosed mantle cell lymphoma. The CHOP + rituximab and hyperCVAD + rituximab regimens are most commonly used. The former is limited by relatively lower rates of complete remission (CR) and frequent relapses. The latter is limited by toxicities, especially in older patients, and relapses that occur later than ...
Margaret, Yu, Elliot, Epner
openaire +2 more sources
Histopathology of Mantle Cell Lymphoma
Seminars in Hematology, 2011Mantle cell lymphoma (MCL) is a relatively rare lymphoma, accounting for less than 10% only of all lymphomas. Its morphology is quite homogeneous, but it varies strikingly in about 10% of the cases, making the diagnosis of MCL challenging for histopathologists. The definition of the disease was greatly influenced by the discovery of the translocation t(
openaire +2 more sources